Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms - Summary - MDSpire

Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms

  • By

  • Samantha A. Banks

  • Paul Decker

  • Eoin P. Flanagan

  • Anastasia Zekeridou

  • Ronald S. Go

  • Jithma P. Abeykoon

  • Gaurav Goyal

  • Jason R. Young

  • Matthew J. Koster

  • Robert Vassallo

  • Jay H. Ryu

  • Caroline J. Davidge-Pitts

  • Aishwarya Ravindran

  • Julio C. Sartori Valinotti

  • N. Nora Bennani

  • Mithun V. Shah

  • Karen L. Rech

  • Corrie R. Bach

  • Jeanette E. Eckel-Passow

  • W. Oliver Tobin

  • September 5, 2024

  • 0 min

Share

Objective:

To evaluate if elevated neurofilament light chain (NfL) levels in patients with specific types of histiocytic neoplasms are associated with CNS involvement and active CNS disease.

Key Findings:
  • NfL levels were significantly elevated in patients with CNS histiocytosis compared to those without (P < 0.0001).
  • Patients with parenchymal CNS involvement had higher NfL levels than those without CNS involvement (P < 0.0001).
  • BRAF V600E mutation was present in 43% of tested patients, with a higher prevalence in those with CNS involvement.
Interpretation:

Elevated NfL levels correlate with CNS involvement and disease activity in patients with histiocytic neoplasms, suggesting its potential as a biomarker for monitoring disease progression.

Limitations:
  • The study's retrospective design may limit the ability to establish causation, potentially affecting the reliability of the findings.
  • Sample size may restrict the generalizability of findings, suggesting caution in applying results to broader populations.
Conclusion:

NfL is a promising biomarker for assessing CNS involvement in histiocytic neoplasms, warranting further investigation for clinical application and potential integration into monitoring protocols.

Original Source(s)

Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms

  • by Samantha A. Banks, Paul Decker, Eoin P. Flanagan, Anastasia Zekeridou, Ronald S. Go, Jithma P. Abeykoon, Gaurav Goyal, Jason R. Young, Matthew J. Koster, Robert Vassallo, Jay H. Ryu, Caroline J. Davidge-Pitts, Aishwarya Ravindran, Julio C. Sartori Valinotti, N. Nora Bennani, Mithun V. Shah, Karen L. Rech, Corrie R. Bach, Jeanette E. Eckel-Passow, W. Oliver Tobin

  • September 5, 2024

Related Content

Machine learning-based pathomics signature of histology slides as a novel prognostic indicator in primary central nervous system lymphoma

Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors

The molecular diagnostic yield of frame-based stereotactic biopsies in the age of precision neuro-oncology: a cross-sectional study